China Biologic to Report First Quarter of 2018 Financial Results
- Provides Preliminary First Quarter 2018 Results and Earnings Announcement Date - BEIJING, April 24, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today a...
China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2017
BEIJING, Feb. 28, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced its financial results for the fourth quarter and fiscal year of 2017. Fourth...
China Biologic Products to Report Fourth Quarter and Fiscal Year 2017 Financial Results
BEIJING, Feb. 23, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that the Company plans to release its fourth quarter and fiscal year of 2017...
China Biologic to Build New Collection Station in Hainan Province
BEIJING, Feb. 14, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that its wholly-owned subsidiary Guizhou Taibang Biological Products Co. Ltd...
China Biologic to Attend the 36th Annual J.P. Morgan Healthcare Conference
BEIJING, Jan. 8, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that the Company will participate in the 36th Annual J.P. Morgan Healthcare Co...
China Biologic Announces Corporate Update
--Provides Update on New Shandong Facility and Full Year 2017 Financial Forecast -- BEIJING, Jan. 8, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today ann...
China Biologic Announces Completion of Acquisition of TianXinFu from PWM
BEIJING, Jan. 3, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ( "CBPO" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that it has completed the acquisition of 80% equity interest in Tianxinfu (Beijing) Me...
China Biologic Receives Operating Permit for New Collection Facility in Ju County in Shandong Province
BEIJING, Dec. 15, 2017 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO)("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that, the Company's majority-owned subsidiary, Shandong Taibang Biological Pr...
China Biologic Reports Unaudited Financial Results for the Third Quarter of 2017
BEIJING, Nov. 1, 2017 /PRNewswire/ --China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced its unaudited financial results for the third quarter of 2017. Third Quarter 2...
China Biologic Products to Report Third Quarter of 2017 Financial Results
BEIJING, Oct. 25, 2017 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that the Company plans to release third quarter of 2017 financial results on...
China Biologic Products Announces Conference Call to Discuss TianXinFu Acquisition
BEIJING, Oct. 13, 2017 /PRNewswire/ -- China Biologic Products Holding, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that the Company will host a conferencecall to discuss the TianXinFu acquisit...
China Biologic Agrees to Acquire TianXinFu from PWM
BEIJING, Oct. 12, 2017 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("CBPO" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that it has agreed to acquire 80% equity interest in Tianxinfu (Beijing) Medical Appli...
China Biologic Receives Approval for Commercial Manufacturing of Human Fibrinogen
BEIJING, Oct. 9. 2017 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that Shandong Taibang Biological Products Co., Ltd. ("Shandong Taibang"), the ...
China Biologic Reports Financial Results for the Second Quarter of 2017
--2Q17 Total Sales Up 2.5% YoY and Non-GAAP Adjusted Net Income Up 15.0% YoY in RMB terms,or Total Sales Down 2.3% YoY to $89.3 Million and Net Income Up 0.6% YoY to$31.0 Million in USD terms-- --1H17 Total Sales Up 7.4% YoY and Non-GAAP Adjusted Net Income Up 21.8% YoY in RMB terms,or Total Sa...
China Biologic Products to Report Second Quarter of 2017 Financial Results
BEIJING, July 19, 2017 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that the Company plans to release second quarter of 2017 financial results onWednesda...
China Biologic Announces Effectiveness of Registration Statement and Mailing of Definitive Proxy Statement/Prospectus for 2017 Annual Meeting of Stockholders
BEIJING, May 19, 2017 /PRNewswire/ -- China Biologic Products, Inc. ("China Biologic" or the "Company") (NASDAQ: CBPO), a leading fully integrated plasma-based biopharmaceutical company inChina, announced today that the Securities and Exchange Commission has declared effective a Form F-4 Registr...
China Biologic Reports Financial Results for the First Quarter of 2017
--1Q17 Total Sales Up 6.9% YoY to $91.5Million and Net Income Up 14.5% YoY to $30.0 Million in USD terms, or Total Sales Up 12.7% YoY and Non-GAAP Adjusted Net Income Up 29.7% YoY in RMB terms-- --Reiterates Full Year Financial Forecast-- BEIJING, May 3, 2017 /PRNewswire/ -- China Biologic Produ...
China Biologic Products to Report First Quarter of 2017 Financial Results
BEIJING, China, April 21, 2017 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that the Company plans to release first quarter of 2017 financial results onW...
